GENE ONLINE|News &
Opinion
Blog

Korean Firm, Asia’s First to Get FDA Clearance for Testing Anti-Cancer Microbiome Therapeutic

by Judy Ya-Hsuan Lin
Share To

By Judy Ya-Hsuan Lin

Genome & Company, a clinical-stage biotech headquartered in South Korea, announces a key milestone for its first anti-cancer microbiome therapeutic, GEN-001. On April 20th this year, the company received FDA Investigational New Drug (IND) clearance to further research into the efficacy and safety of its drug in combination with the previously developed anti-PD-L1 drug, Bavencio (avelumab) to treat cancers. Launched in 2015, Genome & Company focuses on developing innovative therapeutics in immune-oncology with specialization in immune checkpoint inhibitors and fusion proteins. The FDA clearance will further reinforce its status in the microbiome and immune-oncology industry, according to CTO officer, Dr. Hansoo Park, and CEO, Dr. Jisoo Pae.

 

The GEN-001, Avelumab Combo

Earlier this year, the firm signed a collaboration with Merck KGa, Darmstadt, Germany, and Pfizer Inc. to conduct clinical trials with the GEN-001 and avelumab combination. Avelumab is an FDA approved monoclonal antibody therapy for pediatric patients with metastatic Merkel cell carcinoma (mMCC) that is currently evaluated in several trials for treating other cancers. Last May, the drug was approved in combination with Axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The therapy is available in 50 countries with low restrictions on treatment guidelines. The phase 1/1b clinical trial that tests the combination of the two drugs will be conducted in the US, and potentially, the first patient will be enrolled within this year.

Both GEN-001 and avelumab aim to treat cancers, but their targets vary. GEN-001, an oral microbiome therapeutic candidate, is compatible with immune checkpoint inhibitors because of its immune-modulating activities. GEN-001 can be found as a single strain bacterium in the human gut and is responsible for activating dendritic cells, T cell response, and macrophages.

 

Safety of Combination Therapy

When administered as a combination therapy, GEN-001 was found to reduce the growth of both immune checkpoint inhibitor sensitive and resistant tumors. Most importantly, it shows an optimal safety margin in preclinical studies. Avelumab is known to cause several adverse effects, namely fatigue, musculoskeletal pain, nausea, diarrhea, or peripheral edema among others. Previously, its combination with axitinib did not show any signs of reduction. Nevertheless, the GEN-001 combination with avelumab would be anticipated to perform better because of the promise it showed in safety evaluations thus far.

Related Article: Bavencio Meets Primary Endpoint in Bladder Cancer Trial

References
  1. https://www.prnewswire.com/news-releases/genome–company-receives-fda-ind-clearance-for-gen-001-its-first-anti-cancer-microbiome-therapeutic-301043307.html

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
The Latest Talk in Cancer Immunotherapy: A Brief Overview of Developments & Current Players in the Exosome Space
2025-04-23
From Cancer to Cosmetics, Physiological to Pathological – The Field of Exosomes Full of Endless Opportunities
2025-04-22
LATEST
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025
2025-04-27
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top